Bioceltix is a biotech start-up which deals with the development of stem cell-based medicinal products for veterinary use. Currently, our main goal is to implement a biopharmaceuticals based on allogenic stem cells. The medicines will be primarily to serve the treatment of accompanying animals.
The new product candidates will become a milestone in the field of stem cell-based biopharmaceuticals for veterinary use.
As one of the first such Europe-based company, Bioceltix product intends to go through the full registration path to a marketed drugs devised by the European Medicines Agency (EMA). In the first place, there will be a clinical trials carried out, while the positive results of it will allow us for the submissions of an applications for marketing authorization for the drugs we are developing in the territory of the E.U.